In July 2025, the Xcite brand set a new sales record in Russia, selling 2043 vehicles through the Lada dealer network. This is 26.3% more than in June, and 159.9% higher than in July 2024. The X-Cross 7 crossover made the main contribution, with 1700 units sold, while 343 buyers purchased the flagship X-Cross 8. Since the beginning of the year, 5874 Xcite cars have been sold in Russia.
The company has extended the discounts on its crossovers. For the X-Cross 7, the benefit reaches 650,000 rubles, and the minimum price is 1,849,000 rubles. For the X-Cross 8, discounts reach up to 750,000 rubles, with a starting price of 2,249,000 rubles. The X-Cross 7 is equipped with a 1.5-liter turbocharged engine with 147 hp and a CVT, available only with front-wheel drive. The X-Cross 8 is offered with all-wheel drive, a 1.6-liter TGDI engine with 150 hp, and a 7-speed robotic gearbox.
The cars are assembled at the "Avtozavod St. Petersburg" plant, which is currently on corporate leave. Lada Iskra production will begin at the plant in September.
Read more materials:
Dream of Soviet boys: pedal "Moskvich" put up for sale in Barnaul
"Moskvich-412" in the state of "time capsule" appeared on sale in Russia
Unusual Russian supercar CN3500 photographed: engine produces 350 hp
Now on home
The injury reduces the reliability of the grip and can lead to loss of control over the car
Developed by Zavoz.pro, it doesn't burn and doesn't absorb moisture
New feature may launch by the end of 2025
According to Mediascope, the average daily viewing time on the service increased by 40%
The development belongs to the "Molniya" enterprise
The State Corporation Announced Plans for 2026
Разблокировать сервис можно через «Цифровой ID» в национальном мессенджере Max
Trade Representative Dakhnovsky: Russia is open to industrial integration
A unified model for interaction with RMS reduces integration costs and shortens timelines
The equipment ensures precise aircraft landing in poor visibility conditions
The technologies will be used in navigation, mineral exploration, and biomedical research